
Ioannis E Koutroubakis

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3723455/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The First European Evidence-based Consensus on Extra-intestinal Manifestations in Inflammatory Bowel Disease. Journal of Crohn's and Colitis, 2016, 10, 239-254.	1.3	577
2	European Consensus on the Diagnosis and Management of Iron Deficiency and Anaemia in Inflammatory Bowel Diseases. Journal of Crohn's and Colitis, 2015, 9, 211-222.	1.3	425
3	Guidelines on the diagnosis and management of iron deficiency and anemia in inflammatory bowel diseases#. Inflammatory Bowel Diseases, 2007, 13, 1545-1553.	1.9	373
4	Mean platelet volume: a useful marker of inflammatory bowel disease activity. American Journal of Gastroenterology, 2001, 96, 776-781.	0.4	279
5	Circulating levels of leptin, adiponectin, resistin, and ghrelin in inflammatory bowel disease. Inflammatory Bowel Diseases, 2006, 12, 100-105.	1.9	259
6	Ischemic colitis: Clinical practice in diagnosis and treatment. World Journal of Gastroenterology, 2008, 14, 7302.	3.3	216
7	Phenotype at diagnosis predicts recurrence rates in Crohn's disease. Gut, 2005, 55, 1124-1130.	12.1	207
8	Allelic polymorphism in IL-1β and IL-1 receptor antagonist (IL-1Ra) genes in inflammatory bowel disease. Clinical and Experimental Immunology, 2008, 102, 379-383.	2.6	182
9	Dietary Guidance From the International Organization for the Study of Inflammatory Bowel Diseases. Clinical Gastroenterology and Hepatology, 2020, 18, 1381-1392.	4.4	161
10	Association of Vitamin D Level With Clinical Status in Inflammatory Bowel Disease: A 5-Year Longitudinal Study. American Journal of Gastroenterology, 2016, 111, 712-719.	0.4	156
11	Distribution of four polymorphisms in the tumour necrosis factor (TNF) genes in patients with inflammatory bowel disease (IBD). Clinical and Experimental Immunology, 2007, 103, 391-396.	2.6	133
12	Prevalence of Anemia in Inflammatory Bowel Diseases in European Countries. Inflammatory Bowel Diseases, 2014, 20, 936-945.	1.9	129
13	Impact of Obesity on the Management and Clinical Course of Patients with Inflammatory Bowel Diseases, 2015, 21, 2857-2863.	1.9	129
14	Role of Appendicitis and Appendectomy in the Pathogenesis of Ulcerative Colitis: A Critical Review. Inflammatory Bowel Diseases, 2002, 8, 277-286.	1.9	125
15	Appendectomy and the development of ulcerative colitis: results of a metaanalysis of published case-control studies. American Journal of Gastroenterology, 2000, 95, 171-176.	0.4	124
16	Development of an index to define overall disease severity in IBD. Gut, 2018, 67, 244-254.	12.1	108
17	Prevalence and Characteristics of Extra-intestinal Manifestations in a Large Cohort of Greek Patients with Inflammatory Bowel Disease. Journal of Crohn's and Colitis, 2016, 10, 429-436.	1.3	106
18	Decreased Total and Corrected Antioxidant Capacity in Patients with Inflammatory Bowel Disease. Digestive Diseases and Sciences, 2004, 49, 1433-1437.	2.3	96

#	Article	IF	CITATIONS
19	Role of angiogenesis in inflammatory bowel disease. Inflammatory Bowel Diseases, 2006, 12, 515-523.	1.9	95
20	Resistance to activated protein C and low levels of free protein S in Greek patients with inflammatory bowel disease. American Journal of Gastroenterology, 2000, 95, 190-194.	0.4	91
21	Leptin, adiponectin, resistin, and ghrelin – Implications for inflammatory bowel disease. Molecular Nutrition and Food Research, 2008, 52, 855-866.	3.3	87
22	The spectrum of segmental colitis associated with diverticulosis. International Journal of Colorectal Disease, 2005, 20, 28-32.	2.2	82
23	Budesonide 9 mg Is at Least as Effective as Mesalamine 4.5 g in Patients With Mildly to Moderately Active Crohn's Disease. Gastroenterology, 2011, 140, 425-434.e1.	1.3	82
24	Fecal Calprotectin in Assessing Inflammatory Bowel Disease Endoscopic Activity: a Diagnostic Accuracy Meta-analysis. Journal of Gastrointestinal and Liver Diseases, 2019, 27, 299-306.	0.9	82
25	Anti-cardiolipin and anti-beta2-glycoprotein I antibodies in patients with inflammatory bowel disease. Digestive Diseases and Sciences, 1998, 43, 2507-2512.	2.3	81
26	Therapy Insight: vascular complications in patients with inflammatory bowel disease. Nature Reviews Gastroenterology & Hepatology, 2005, 2, 266-272.	1.7	80
27	Multipotent role of platelets in inflammatory bowel diseases: A clinical approach. World Journal of Gastroenterology, 2014, 20, 3180.	3.3	74
28	Increased serum levels of YKL-40 in patients with inflammatory bowel disease. International Journal of Colorectal Disease, 2003, 18, 254-259.	2.2	72
29	Diagnosing anemia in inflammatory bowel disease: Beyond the established markers. Journal of Crohn's and Colitis, 2011, 5, 381-391.	1.3	72
30	Demographic and Clinical Predictors of High Healthcare Use in Patients with Inflammatory Bowel Diseases, 2016, 22, 1442-1449.	1.9	72
31	Anti– Saccharomyces Cerevisiae Mannan Antibodies and Antineutrophil Cytoplasmic Autoantibodies in Greek Patients With Inflammatory Bowel Disease. American Journal of Gastroenterology, 2001, 96, 449-454.	0.4	70
32	Serum hepcidin and prohepcidin concentrations in inflammatory bowel disease. European Journal of Gastroenterology and Hepatology, 2011, 23, 262-268.	1.6	68
33	Selecting End Points for Disease-Modification Trials in Inflammatory Bowel Disease: the SPIRIT Consensus From the IOIBD. Gastroenterology, 2021, 160, 1452-1460.e21.	1.3	68
34	Somatostatin for acute severe bleeding from portal hypertensive gastropathy. European Journal of Gastroenterology and Hepatology, 1998, 10, 509-512.	1.6	64
35	Persistent or Recurrent Anemia Is Associated With Severe and Disabling Inflammatory Bowel Disease. Clinical Gastroenterology and Hepatology, 2015, 13, 1760-1766.	4.4	62
36	The Emerging Role of Adipocytokines as Inflammatory Mediators in Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2005, 11, 847-855.	1.9	59

#	Article	IF	CITATIONS
37	Appendectomy, tonsillectomy, and risk of inflammatory bowel disease. Diseases of the Colon and Rectum, 1999, 42, 225-230.	1.3	57
38	Analysis of Hospital-Based Emergency Department Visits for Inflammatory Bowel Disease in the USA. Digestive Diseases and Sciences, 2016, 61, 389-399.	2.3	53
39	Hyperhomocysteinemia in Greek patients with inflammatory bowel disease. Digestive Diseases and Sciences, 2000, 45, 2347-2351.	2.3	51
40	A case of sigmoid endometriosis difficult to differentiate from colon cancer. BMC Gastroenterology, 2003, 3, 18.	2.0	50
41	Measurement of reticulocyte and red blood cell indices in the evaluation of anemia in inflammatory bowel disease. Journal of Crohn's and Colitis, 2011, 5, 295-300.	1.3	50
42	Serum Angiogenin in Inflammatory Bowel Disease. Digestive Diseases and Sciences, 2004, 49, 1758-1762.	2.3	49
43	Results of the Fifth Scientific Workshop of the ECCO [II]: Clinical Aspects of Perianal Fistulising Crohn's Disease—the Unmet Needs. Journal of Crohn's and Colitis, 2016, 10, 758-765.	1.3	49
44	A Prospective Epidemiologic Study of Crohn's Disease in Heraklion, Crete Incidence over a 5-Year Period. Scandinavian Journal of Gastroenterology, 1996, 31, 599-603.	1.5	48
45	The effect of infliximab on circulating levels of leptin, adiponectin and resistin in patients with inflammatory bowel disease. European Journal of Gastroenterology and Hepatology, 2007, 19, 789-794.	1.6	47
46	Genetic Risk Factors In Patients With Inflammatory Bowel Disease And Vascular Complications: Case-Control Study. Inflammatory Bowel Diseases, 2007, 13, 410-415.	1.9	47
47	Effects of tumor necrosis factor alpha inhibition with infliximab on lipid levels and insulin resistance in patients with inflammatory bowel disease. European Journal of Gastroenterology and Hepatology, 2009, 21, 283-288.	1.6	46
48	Thrombosis and inflammatory bowel disease-the role of genetic risk factors. World Journal of Gastroenterology, 2008, 14, 4440.	3.3	45
49	Safety and Efficacy of Total-Dose Infusion of Low Molecular Weight Iron Dextran for Iron Deficiency Anemia in Patients with Inflammatory Bowel Disease. Digestive Diseases and Sciences, 2010, 55, 2327-2331.	2.3	44
50	Risk of Venous Thromboembolism in Patients with Inflammatory Bowel Disease. Seminars in Thrombosis and Hemostasis, 2013, 39, 461-468.	2.7	44
51	Hypercoagulable States in Patients with Hepatocellular Carcinoma. Digestive Diseases and Sciences, 2004, 49, 854-858.	2.3	43
52	Serum laminin and collagen IV in inflammatory bowel disease. Journal of Clinical Pathology, 2003, 56, 817-820.	2.0	42
53	Association Between Long-Term Lipid Profiles and Disease Severity in a Large Cohort of Patients with Inflammatory Bowel Disease. Digestive Diseases and Sciences, 2016, 61, 865-871.	2.3	42
54	Increased expression of chemokine receptor CCR3 and its ligands in ulcerative colitis: the role of colonic epithelial cells in <i>in vitro</i> studies. Clinical and Experimental Immunology, 2010, 162, 337-347.	2.6	41

#	Article	IF	CITATIONS
55	Peripheral Eosinophilia in Patients With Inflammatory Bowel Disease Defines an Aggressive Disease Phenotype. American Journal of Gastroenterology, 2017, 112, 1849-1858.	0.4	41
56	Potential role of soluble angiopoietin-2 and Tie-2 in patients with inflammatory bowel disease. European Journal of Clinical Investigation, 2006, 36, 127-132.	3.4	40
57	Increased expression of VECF and CD146 in patients with inflammatory bowel disease. Digestive and Liver Disease, 2008, 40, 673-679.	0.9	40
58	Silent Crohn's Disease. Inflammatory Bowel Diseases, 2015, 21, 1.	1.9	40
59	lleocecal Anastomosis Type Significantly Influences Long-Term Functional Status, Quality of Life, and Healthcare Utilization in Postoperative Crohn's Disease Patients Independent of Inflammation Recurrence. American Journal of Gastroenterology, 2018, 113, 576-583.	0.4	40
60	Increased levels of lipoprotein (a) in Crohn's disease: a relation to thrombosis?. European Journal of Gastroenterology and Hepatology, 2001, 13, 1415-1419.	1.6	38
61	Elevated Thrombopoietin Serum Levels in Patients With Inflammatory Bowel Disease. American Journal of Gastroenterology, 2000, 95, 3478-3481.	0.4	37
62	Effectiveness of darbepoetin-alfa in combination with intravenous iron sucrose in patients with inflammatory bowel disease and refractory anaemia: a pilot study. European Journal of Gastroenterology and Hepatology, 2006, 18, 421-425.	1.6	37
63	Plasma thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 levels in inflammatory bowel disease. European Journal of Gastroenterology and Hepatology, 2008, 20, 912-916.	1.6	37
64	Chemerin, visfatin, and vaspin serum levels in relation to bone mineral density in patients with inflammatory bowel disease. European Journal of Gastroenterology and Hepatology, 2016, 28, 814-819.	1.6	36
65	Ulcerative colitis associated with primary biliary cirrhosis. Digestive Diseases and Sciences, 1999, 44, 1953-1956.	2.3	35
66	Role of Thrombotic Vascular Risk Factors in Inflammatory Bowel Disease. Digestive Diseases, 2000, 18, 161-167.	1.9	35
67	Stimulating erythropoiesis in inflammatory bowel disease associated anemia. World Journal of Gastroenterology, 2007, 13, 4798.	3.3	35
68	Five-Year Period Prevalence and Characteristics of Anemia in a Large US Inflammatory Bowel Disease Cohort. Journal of Clinical Gastroenterology, 2016, 50, 638-643.	2.2	35
69	Soluble transferrin receptor-ferritin index in the evaluation of anemia in inflammatory bowel disease: a case-control study. Annals of Gastroenterology, 2011, 24, 108-114.	0.6	34
70	Acquired inhibitors to coagulation factors in patients with gastrointestinal diseases. European Journal of Gastroenterology and Hepatology, 2002, 14, 1383-1387.	1.6	33
71	Association between enhanced soluble CD40 ligand and prothrombotic state in inflammatory bowel disease. European Journal of Gastroenterology and Hepatology, 2004, 16, 1147-1152.	1.6	33
72	The Influence of Anti–tumor Necrosis Factor Agents on Hemoglobin Levels of Patients with Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2015, 21, 1587-1593.	1.9	33

#	Article	IF	CITATIONS
73	Quality of Sleep and Coexistent Psychopathology Have Significant Impact on Fatigue Burden in Patients With Inflammatory Bowel Disease. Journal of Clinical Gastroenterology, 2018, 52, 423-430.	2.2	33
74	Association between thrombocytosis and iron deficiency anemia in inflammatory bowel disease. European Journal of Gastroenterology and Hepatology, 2013, 25, 1.	1.6	31
75	The Association Between Sustained Poor Quality of Life and Future Opioid Use in Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2018, 24, 1380-1388.	1.9	31
76	Colonic tuberculosis mimicking Crohn's disease: case report. BMC Gastroenterology, 2002, 2, 10.	2.0	29
77	Soluble transferrin receptor-ferritin index is the most efficient marker for the diagnosis of iron deficiency anemia in patients with IBD. Inflammatory Bowel Diseases, 2011, 17, E158-E159.	1.9	29
78	Inflammatory Bowel Disease [IBD] and Physical Activity: A Study on the Impact of Diagnosis on the Level of Exercise Amongst Patients With IBD. Journal of Crohn's and Colitis, 2019, 13, 686-692.	1.3	29
79	Development of an Inflammatory Bowel Disease Research Registry Derived from Observational Electronic Health Record Data for Comprehensive Clinical Phenotyping. Digestive Diseases and Sciences, 2016, 61, 3236-3245.	2.3	28
80	Role of scintigraphy in inflammatory bowel disease. World Journal of Gastroenterology, 2009, 15, 2693.	3.3	28
81	Recent advances in the management of distal ulcerative colitis. World Journal of Gastrointestinal Pharmacology and Therapeutics, 2010, 1, 43.	1.1	28
82	NOD2 insertion mutation in a cretan Crohn's disease population. Gastroenterology, 2003, 124, 272-273.	1.3	27
83	Silent Crohn's Disease Predicts Increased Bowel Damage During Multiyear Follow-up. Inflammatory Bowel Diseases, 2016, 22, 2665-2671.	1.9	27
84	Ulcerative colitis is as common in Crete as in northern Europe: a 5-year prospective study. European Journal of Gastroenterology and Hepatology, 1996, 8, 893-8.	1.6	27
85	Unraveling the Mechanisms of Thrombosis in Inflammatory Bowel Disease. American Journal of Gastroenterology, 2001, 96, 1325-1327.	0.4	26
86	Lasting Impact of Clostridium difficile Infection in Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2017, 23, 2180-2188.	1.9	26
87	Epithelioid Granulomas Associate With Increased Severity and Progression of Crohn's Disease, Based on 6-Year Follow-Up. Clinical Gastroenterology and Hepatology, 2018, 16, 900-907.e1.	4.4	26
88	Interstitial and Granulomatous Lung Disease in Inflammatory Bowel Disease Patients. Journal of Crohn's and Colitis, 2020, 14, 480-489.	1.3	26
89	Active Inflammatory Bowel Disease: Evaluation with ^{99m} Tc (V) DMSA Scintigraphy. Radiology, 2003, 229, 70-74.	7.3	25
90	The Cost of Crohn's Disease. Inflammatory Bowel Diseases, 2017, 23, 107-115.	1.9	24

#	Article	IF	CITATIONS
91	Genetic Risk Factors in Young Patients With Ischemic Colitis. Clinical Gastroenterology and Hepatology, 2008, 6, 907-911.	4.4	21
92	Opioid Analgesics Do Not Improve Abdominal Pain or Quality of Life in Crohn's Disease. Digestive Diseases and Sciences, 2020, 65, 2379-2387.	2.3	20
93	Disease Characteristics and Severity in Patients With Inflammatory Bowel Disease With Coexistent Diabetes Mellitus. Inflammatory Bowel Diseases, 2020, 26, 1436-1442.	1.9	20
94	Association between ulcerative colitis and systemic lupus erythematosus. European Journal of Gastroenterology and Hepatology, 1998, 10, 437-440.	1.6	19
95	Prognostic Significance of the Detection of Peripheral Blood CEACAM5mRNA-Positive Cells by Real-Time Polymerase Chain Reaction in Operable Colorectal Cancer. Clinical Cancer Research, 2011, 17, 165-173.	7.0	19
96	Aortic Stiffening Is an Extraintestinal Manifestation of Inflammatory Bowel Disease: Review of the Literature and Expert Panel Statement. Angiology, 2020, 71, 689-697.	1.8	19
97	Pancreatic Autoantibodies in Greek Patients with Inflammatory Bowel Disease. Digestive Diseases and Sciences, 2005, 50, 2330-2334.	2.3	18
98	Endpoints for extraintestinal manifestations in inflammatory bowel disease trials: the EXTRA consensus from the International Organization for the Study of Inflammatory Bowel Diseases. The Lancet Gastroenterology and Hepatology, 2022, 7, 254-261.	8.1	18
99	Idiopathic fibrosing pancreatitis and Crohn's disease. European Journal of Gastroenterology and Hepatology, 2000, 12, 1021-1024.	1.6	16
100	A case of orbital myositis preceding the intestinal symptoms of Crohn's disease. Journal of Crohn's and Colitis, 2010, 4, 349-350.	1.3	16
101	Venous Thromboembolism in Hospitalized Inflammatory Bowel Disease Patients: The Magnitude of the Problem Is Staggering. American Journal of Gastroenterology, 2008, 103, 2281-2283.	0.4	14
102	Active inflammatory bowel disease: head-to-head comparison between 99mTc-hexamethylpropylene amine oxime white blood cells and 99mTc(V)-dimercaptosuccinic acid scintigraphy. Nuclear Medicine Communications, 2008, 29, 27-32.	1.1	14
103	Role of Chrelin and Insulin-like Growth Factor Binding Protein-3 in the Development of Osteoporosis in Inflammatory Bowel Disease. Journal of Clinical Gastroenterology, 2011, 45, e60-e65.	2.2	14
104	Anal adenocarcinoma complicating chronic Crohn's disease. International Journal of Surgery Case Reports, 2015, 10, 201-203.	0.6	14
105	Multiyear Patterns of Serum Inflammatory Biomarkers and Risk of Colorectal Neoplasia in Patients with Ulcerative Colitis. Inflammatory Bowel Diseases, 2016, 22, 100-105.	1.9	14
106	Group-Based Trajectory Modeling of Healthcare Financial Charges in Inflammatory Bowel Disease: A Comprehensive Phenotype. Clinical and Translational Gastroenterology, 2016, 7, e181.	2.5	14
107	Spectrum of non-inflammatory bowel disease and non-infectious colitis. World Journal of Gastroenterology, 2008, 14, 7277.	3.3	14
108	Low plasma protein Z levels in patients with ischemic colitis. Digestive Diseases and Sciences, 2003, 48, 1673-1676.	2.3	13

#	Article	IF	CITATIONS
109	Patterns of Antibiotic Exposure and Clinical Disease Activity in Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2015, 21, 2576-2582.	1.9	13
110	Delineation of Crohn's Disease Trajectories Using Change in Lémann Index. Journal of Clinical Gastroenterology, 2016, 50, 476-482.	2.2	13
111	Infliximab trough levels are decreasing over time in patients with inflammatory bowel disease on maintenance treatment with infliximab. European Journal of Gastroenterology and Hepatology, 2019, 31, 187-191.	1.6	12
112	Is there any role of renin-angiotensin system inhibitors in modulating inflammatory bowel disease outcome?. European Journal of Gastroenterology and Hepatology, 2021, 33, 364-371.	1.6	12
113	Treatment of oesophageal Crohn's disease with infliximab. European Journal of Gastroenterology and Hepatology, 2004, 16, 431-432.	1.6	11
114	Antibodies Against Cyclic Citrullinated Peptide (CCP) in Inflammatory Bowel Disease Patients With or Without Arthritic Manifestations. Inflammatory Bowel Diseases, 2007, 13, 504-505.	1.9	11
115	The relationship between coagulation state and inflammatory bowel disease: current understanding and clinical implications. Expert Review of Clinical Immunology, 2015, 11, 479-488.	3.0	11
116	Low Rates of Dermatologic Care and Skin Cancer Screening Among Inflammatory Bowel Disease Patients. Digestive Diseases and Sciences, 2018, 63, 2729-2739.	2.3	11
117	Iron Sucrose: A Wealth of Experience in Treating Iron Deficiency. Advances in Therapy, 2020, 37, 1960-2002.	2.9	11
118	Monocytosis Is a Biomarker of Severity in Inflammatory Bowel Disease: Analysis of a 6-Year Prospective Natural History Registry. Inflammatory Bowel Diseases, 2022, 28, 70-78.	1.9	11
119	Circulating soluble vascular adhesion protein 1 in patients with inflammatory bowel disease. European Journal of Gastroenterology and Hepatology, 2002, 14, 405-408.	1.6	10
120	JAK2 V617F mutation is not involved in thromboembolism in IBD. Inflammatory Bowel Diseases, 2008, 14, 1606-1607.	1.9	10
121	New desensitization regimen with mesalamine granules in a patient with ulcerative colitis and mesalamine intolerance. Inflammatory Bowel Diseases, 2011, 17, E8-E9.	1.9	10
122	The Bone and Fat Connection in Inflammatory Bowel Diseases. Inflammatory Bowel Diseases, 2014, 20, 2207-2217.	1.9	10
123	Peripheral Blood Eosinophilia and Long-term Severity in Pediatric-Onset Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2020, 26, 1890-1900.	1.9	10
124	Chemoprevention of colorectal cancer in inflammatory bowel disease? A potential role for folate. Italian Journal of Gastroenterology and Hepatology, 1998, 30, 421-5.	0.5	10
125	Resistin: another rising biomarker in inflammatory bowel disease?. European Journal of Gastroenterology and Hepatology, 2007, 19, 1035-1037.	1.6	9
126	Correlation of anemia status with worsening bowel damage as measured by Lémann Index in patients with Crohn's disease. Digestive and Liver Disease, 2016, 48, 626-631.	0.9	9

#	Article	IF	CITATIONS
127	Low bone mineral density in Greek patients with inflammatory bowel disease: prevalence and risk factors. Annals of Gastroenterology, 2011, 24, 41-46.	0.6	9
128	Evidence of genetic heterogeneity in IBD: 1. The interleukin-1 receptor antagonist in the predisposition to suffer from ulcerative colitis. European Journal of Gastroenterology and Hepatology, 1996, 8, 105-10.	1.6	9
129	IOIBD Recommendations for Clinical Trials in Ulcerative Proctitis: The PROCTRIAL Consensus. Clinical Gastroenterology and Hepatology, 2022, 20, 2619-2627.e1.	4.4	9
130	Assaying of Tumor Necrosis Factor α, Complement Factors, and α-1-Antitrypsin in the Diagnosis of Malignant Serous Effusions. American Journal of Clinical Oncology: Cancer Clinical Trials, 2001, 24, 562-565.	1.3	8
131	Small bowel perforation due to non-Hodgkin-lymphoma in a patient with ulcerative colitis and systemic lupus erythematosus. Digestive and Liver Disease, 2008, 40, 144.	0.9	8
132	Disseminated tuberculosis in a Crohn's disease patient on anti-TNFÂ therapy despite chemoprophylaxis. Gut, 2008, 57, 425-425.	12.1	8
133	Asymptomatic hyperCKemia During Infliximab Therapy in Patients With Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2018, 24, 1266-1271.	1.9	8
134	Prevalence of Clostridium difficile infection among hospitalized inflammatory bowel disease patients in Greece. European Journal of Gastroenterology and Hepatology, 2019, 31, 773-776.	1.6	8
135	The burden and management of anemia in Greek patients with inflammatory bowel disease: a retrospective, multicenter, observational study. BMC Gastroenterology, 2021, 21, 269.	2.0	8
136	Immunogenetics of Cytokines: Relevance for Future Research on Inflammatory Bowel Disease. Scandinavian Journal of Gastroenterology, 1995, 30, 1139-1146.	1.5	7
137	Anti-TNF and Fistulising Perianal Crohns Disease: Use in Clinical Practice. Current Drug Targets, 2010, 11, 187-197.	2.1	7
138	Antiglycan Antibodies in Greek Patients with Inflammatory Bowel Disease. Digestive Diseases and Sciences, 2011, 56, 845-852.	2.3	7
139	European experience with methotrexate treatment in Crohn's disease: a multicenter retrospective analysis. European Journal of Gastroenterology and Hepatology, 2016, 28, 802-806.	1.6	7
140	Mean platelet volume: a useful marker of inflammatory bowel disease activity. American Journal of Gastroenterology, 2001, 96, 776-781.	0.4	7
141	Treatment of anaemia in inflammatory bowel disease. Alimentary Pharmacology and Therapeutics, 2006, 23, 1273-1274.	3.7	6
142	Increased Fracture Risk Assessed by Fracture Risk Assessment Tool in Greek Patients with Crohn's Disease. Digestive Diseases and Sciences, 2013, 58, 216-221.	2.3	6
143	Use of vedolizumab in a patient with chronic and refractory pouchitis. Annals of Gastroenterology, 2018, 31, 379.	0.6	6
144	Is there a role for Tc-99m (V) DMSA scintigraphy in ischemic colitis?. World Journal of Gastroenterology, 2008, 14, 5432.	3.3	6

#	Article	IF	CITATIONS
145	Real-World Use and Adverse Events of SARS-CoV-2 Vaccination in Greek Patients with Inflammatory Bowel Disease. Journal of Clinical Medicine, 2022, 11, 641.	2.4	6
146	Is there a correlation between infliximab trough levels and the development of adverse events in patients with inflammatory bowel disease?. Intestinal Research, 2021, 19, 461-467.	2.6	5
147	Clinical profiles of moderate and severe Crohn's disease patients and use of anti-tumor necrosis factor agents: Greek expert consensus guidelines. Annals of Gastroenterology, 2015, 28, 417-25.	0.6	5
148	Gastroenteropancreatic Neuroendocrine Neoplasms in Patients with Inflammatory Bowel Disease: An ECCO CONFER Multicentre Case Series. Journal of Crohn's and Colitis, 2022, 16, 940-945.	1.3	5
149	Solid extraintestinal malignancies in patients with inflammatory bowel disease. World Journal of Gastrointestinal Oncology, 2021, 13, 1956-1980.	2.0	5
150	The patient with persistent perianal fistulae. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2007, 21, 503-518.	2.4	4
151	Acute Generalized Exanthematous Pustulosis Induced by Azathioprine in a Patient With Ulcerative Colitis. American Journal of Gastroenterology, 2011, 106, 1005-1007.	0.4	4
152	Prevalence of thiopurine S-methyltransferase gene polymorphisms in patients with inflammatory bowel disease from the island of Crete, Greece. European Journal of Gastroenterology and Hepatology, 2017, 29, 1284-1289.	1.6	4
153	Clinical Characteristics of Inflammatory Bowel Disease Patients Requiring Longâ€Term Parenteral Support in the Present Era of Highly Effective Biologic Therapy. Journal of Parenteral and Enteral Nutrition, 2021, 45, 1100-1107.	2.6	4
154	Keeping on the High Quality of Health Care in Greek Inflammatory Bowel Disease Patients in the SARS-CoV-2 Era. Clinical Gastroenterology and Hepatology, 2020, 18, 2380-2381.	4.4	4
155	The role of coexisting cardiovascular disease on disease severity in patients with inflammatory bowel disease. European Journal of Gastroenterology and Hepatology, 2020, 32, 581-587.	1.6	4
156	Patients With Inflammatory Bowel Diseases Have Impaired Antibody Production After Anti-SARS-CoV-2 Vaccination: Results From a Panhellenic Registry. Inflammatory Bowel Diseases, 2023, 29, 228-237.	1.9	4
157	Anti–saccharomyces cerevisiae mannan antibodies and antineutrophil cytoplasmic autoantibodies in Greek patients with inflammatory bowel disease. American Journal of Gastroenterology, 2001, 96, 449-454.	0.4	3
158	Acquired and hereditary thrombotic risk factors in patients with acute mesenteric vein thrombosis. American Journal of Gastroenterology, 2002, 97, 768-769.	0.4	3
159	99mTc-Leucoscan in the evaluation of inflammatory bowel disease. European Journal of Nuclear Medicine and Molecular Imaging, 2002, 29, 1098-1098.	6.4	3
160	Sa1144 Association Between Surgical Anastomotic Technique and Postoperative Healthcare Financial Burden in Patients With Crohn's Disease: A Longterm, Prospective Study. Gastroenterology, 2015, 148, S-239.	1.3	3
161	Telephone Encounters Predict Future High Financial Expenditures in Inflammatory Bowel Disease Patients. Journal of Clinical Gastroenterology, 2018, 52, 319-325.	2.2	3
162	Elevated thrombopoietin serum levels in patients with inflammatory bowel disease. American Journal of Gastroenterology, 2000, 95, 3478-3481.	0.4	3

#	Article	IF	CITATIONS
163	Distinct features of curculating microparticles and their relationship with disease activity in in inflammatory bowel disease. Annals of Gastroenterology, 2016, 29, 180-7.	0.6	3
164	Eosinophilic gastroenteritis associated with Churg-Strauss syndrome. Annals of Gastroenterology, 2012, 25, 164.	0.6	3
165	Inherited Thrombophilia and Thrombosis in Inflammatory Bowel Disease. American Journal of Gastroenterology, 2006, 101, 403-403.	0.4	2
166	Which patients with IBD are at risk of venous thromboembolism?. Nature Reviews Gastroenterology and Hepatology, 2010, 7, 307-308.	17.8	2
167	Ulcerative colitis and Budd–Chiari syndrome. European Journal of Gastroenterology and Hepatology, 2014, 26, 1306.	1.6	2
168	Lymphangiogenesis in Inflammatory Bowel Disease; A New Therapeutic Target?. Clinical and Translational Gastroenterology, 2016, 7, e154.	2.5	2
169	IBD LIVE Case Series—Case 6. Inflammatory Bowel Diseases, 2016, 22, 2754-2764.	1.9	2
170	Comparison of the Uptake of Screening Colonoscopy between Physicians and the General Population in Greece. Digestive Diseases, 2020, 38, 23-30.	1.9	2
171	Mucocutaneous manifestations in patients with inflammatory bowel disease. European Journal of Gastroenterology and Hepatology, 2021, Publish Ahead of Print, 1387-1393.	1.6	2
172	Appendectomy and the development of ulcerative colitis: results of a metaanalysis of published case-control studies. American Journal of Gastroenterology, 2000, 95, 171-176.	0.4	2
173	Resistance to activated protein C and low levels of free protein S in Greek patients with inflammatory bowel disease. American Journal of Gastroenterology, 2000, 95, 190-194.	0.4	2
174	Hyperhomocysteinemia in greek patients with inflammatory bowel disease. Gastroenterology, 2000, 118, A314.	1.3	1
175	Serum laminin and collagen IV in patients with inflammatory bowel disease. Gastroenterology, 2003, 124, A202-A203.	1.3	1
176	Transient ischaemic colitis following an aeroplane flight. Gut, 2003, 52, 1072-a-1073.	12.1	1
177	Disease activity and venous thromboembolism in inflammatory bowel disease. Lancet, The, 2010, 375, 1689.	13.7	1
178	Cornelia de Lange syndrome in association with ulcerative colitis: A case report. Journal of Crohn's and Colitis, 2013, 7, e399-e400.	1.3	1
179	Su1334 Eosinophilia in Patients With Inflammatory Bowel Disease Is Independently Associated With Increased Healthcare Expenditures: A Prospective 5-Year Experience. Gastroenterology, 2015, 148, S-477-S-478.	1.3	1
180	Su1810 Clostridium difficile Infection in Inflammatory Bowel Disease Predicts Future Healthcare Utilization. Gastroenterology, 2016, 150, S559.	1.3	1

#	Article	IF	CITATIONS
181	Tu1946 Can We Phenotype IBD Patients Based on Financial Charges Over Time? Trajectory Modeling of Healthcare Utilization in a Large, Prospective IBD Cohort. Gastroenterology, 2016, 150, S986-S987.	1.3	1
182	Sa1954 Sickest of the Sick: When Anti-TNF Agents Fail to Halt Progression of Bowel Damage in Crohn's Disease Over Time. Gastroenterology, 2016, 150, S415.	1.3	1
183	Sa1876 Do Epithelioid Granulomas Function As a Biomarker of Severity in Crohn's Disease? Analysis of a Prospective Six-Year Natural History Registry. Gastroenterology, 2016, 150, S387-S388.	1.3	1
184	Extra-pleural Solitary Fibrous Tumor of the Pelvis in a Patient with Crohn's Disease Under Anti-TNF: A Case Report. Inflammatory Bowel Diseases, 2021, 27, e55-e56.	1.9	1
185	Management of Patients with Inflammatory Diseases during the COVID-19 Pandemic. Mediterranean Journal of Rheumatology, 2020, 31, 295.	0.8	1
186	Osteoclast: like giant cell undiferrentiated pancreatic tumor diagnosed by means of EUS guided FNA. Acta Biomedica, 2021, 92, e2021106.	0.3	1
187	Unraveling the mechanisms of thrombosis in inflammatory bowel disease. American Journal of Gastroenterology, 2001, 96, 1325-1327.	0.4	1
188	Hypercoagulable states in patients with hepatocellular carcinoma. Gastroenterology, 2003, 124, A563-A564.	1.3	0
189	Low plasma protein Z levels in patients with colon ischemia. Gastroenterology, 2003, 124, A189.	1.3	0
190	New imaging techniques: promise or passe. Gut, 2003, 52, 1072-1072.	12.1	0
191	Autoimmune pancreatitis. A rare cause of cholestasis. Digestive and Liver Disease, 2011, 43, e3.	0.9	0
192	The Janus Tyrosine Kinase-2 V617F Mutation is Not Implicated in the Pathogenesis of Ischemic Colitis in Young Patients. Journal of Clinical Gastroenterology, 2012, 46, 433-434.	2.2	0
193	Advances in the Management of Inflammatory Bowel Disease. , 2013, , .		0
194	Reply to Polyzos and Kountouras. Inflammatory Bowel Diseases, 2014, 20, E22-E23.	1.9	0
195	Routine Measurement of Quality of Life in Inflammatory Bowel Disease Predicts Future Health Outcomes. American Journal of Gastroenterology, 2016, 111, S270.	0.4	0
196	162 Investigating the Effect of Granulomatous Inflammation on Bowel Damage in Patients With Crohn's Disease: A Natural History Study. Gastroenterology, 2016, 150, S41.	1.3	0
197	1123 Investigating the Changes in Atherosclerotic Cardiovascular Risk Profile of IBD Patients Over 6 Years. Gastroenterology, 2016, 150, S226.	1.3	0
198	Response to van den Heuvel et al Journal of Crohn's and Colitis, 2016, 10, 1374-1374.	1.3	0

#	Article	IF	CITATIONS
199	Tu1932 Long Term Implications of Achieving and Retaining Remission in Crohn's Disease as Defined by Harvey Bradshaw Index. Gastroenterology, 2016, 150, S981.	1.3	Ο
200	Tu1962 Looking Beyond Symptoms and Disease Activity to Define Disease Severity in Inflammatory Bowel Disease: Results of an IOIBD Specialist Panel. Gastroenterology, 2016, 150, S991.	1.3	0
201	Poor Consumption of Fiber, not fat, is Associated with Active Disease in Inflammatory Bowel Disease. Gastroenterology, 2017, 152, S365.	1.3	Ο
202	Is High Globulin Fraction a Biomarker of Severity in Inflammatory Bowel Disease (IBD)? Analysis of a 6-Year, Prospective Natural History Registry. Gastroenterology, 2017, 152, S372.	1.3	0
203	Variation in Annual Rate of Steroid Prescriptions Amongst Providers for Inflammatory Bowel Disease Patients is Dependent on Cohort Size and Disease Severity. Gastroenterology, 2017, 152, S792.	1.3	Ο
204	Letter: is there a role for infliximab biosimilar in patients with inflammatory bowel disease with secondary loss of response to infliximab innovator?. Alimentary Pharmacology and Therapeutics, 2018, 48, 1037-1038.	3.7	0
205	Letter to the Editor: Is There a Role for Switching Infliximab in Order to Regain Anti-TNF Response in Cases With Active Inflammatory Bowel Disease?. Inflammatory Bowel Diseases, 2019, 25, e120-e120.	1.9	0
206	Risk Factors of Colectomy in Patients WithÂRefractory Ulcerative Colitis Under Calcineurin Inhibitors Combined With Vedolizumab. Clinical Gastroenterology and Hepatology, 2019, 17, 1213-1214.	4.4	0
207	Clinical Value of Proactive Infliximab Drug Monitoring in Patients With Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2020, 26, e50.	1.9	0
208	Reply to the letter to the Editor: †The role of coexisting cardiovascular disease on disease severity in patients with inflammatory bowel disease'. European Journal of Gastroenterology and Hepatology, 2021, 32, 300-302.	1.6	0
209	Peripheral Blood Eosinophilia as a Potential Marker of Bowel Damage Progression in Crohn's Disease a 5 Year Natural History Study. American Journal of Gastroenterology, 2016, 111, S287.	0.4	0
210	Comparative Effectiveness of Common Immunomodulator Agents over 5 Year Clinical Outcomes in Crohn's Disease Patients. American Journal of Gastroenterology, 2016, 111, S293-S294.	0.4	0
211	Reply - Fecal calprotectin correlates well with endoscopic activity in ulcerative colitis patients. Journal of Gastrointestinal and Liver Diseases, 2018, 27, 474-475.	0.9	0
212	Pyoderma gangrenosum associated with chronic refractory pouchitis: a case successfully treated with infliximab. Annals of Gastroenterology, 2020, 33, 433-435.	0.6	0
213	New Editorial Board - a new start. Annals of Gastroenterology, 2011, 24, 8.	0.6	0
214	Gastric non-Hodgkin's lymphoma. Annals of Gastroenterology, 2014, 27, 167.	0.6	0
215	Effect of antinuclear antibodies on pharmacokinetics of anti-TNF therapy in patients with inflammatory bowel disease. International Journal of Colorectal Disease, 2022, 37, 639-646.	2.2	0
216	Acquired and hereditary thrombotic risk factors in patients with acute mesenteric vein thrombosis. American Journal of Gastroenterology, 2002, 97, 768-769.	0.4	0